【Abstract】ObjectiveTo explore the clinical curative effect of liraglutide combined with acarbose in the treatment of patients with obesity type 2 diabetes. MethodsA total of 80 patients with obesity type 2 diabetes were randomly divided into group A and group B, with 40 cases in each group, the group A was treated with liraglutide combined with acarbose, while the group B received acarbose alone, the two groups were given regular diet and exercise guidance, the blood glucose, glycosylated hemoglobin (HbA1c), fasting insulin (FINS), blood lipid, body mass index (BMI) and insulin resistance index (HOMAIR) were observed before and after treatment, and the above indexes were compared between the two groups.ResultsThe levels of fasting blood glucose (FPG), postprandial blood glucose (2hPG), glycosylated hemoglobin (HbA1c), cholesterol (Tc), triglyceride (TG) decreased significantly in the two groups after treatment in contrast with those before treatment, and the decreased in the group A was more significant (P＜0.05); after treatment, the body mass index (BMI) and insulin resistance index (HOMAIR) in the group A was significantly lower than those in the group B (P＜0.05), there was no significant difference of body mass index (BMI) and insulin resistance index (HOMAIR) in the group B before and after treatment (P＞0.05). ConclusionsCompare with acarbose, liraglutide combined with acarbose in the treatment of patients with obesity type 2 diabetes can control blood sugar, lose body weight, improve blood lipid metabolism, reduce insulin resistance more effective, and will not increase the incidence rate of hypoglycemia.

无